Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro (tirzepatide) is prescribed in the UK at six doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg, taken once a week by subcutaneous injection. Treatment always starts at 2.5 mg, then steps up roughly every four weeks as your prescriber judges it safe to do so. The final dose you stay on is a clinical decision, not a fixed destination. Because Mounjaro is a prescription-only medicine, the prescribing schedule is set by your prescriber after assessing your individual health picture — no two journeys through the doses look exactly alike. The NHS tirzepatide information page describes the schedule at a patient level, and the Summary of Product Characteristics on the electronic Medicines Compendium (eMC) carries the full licensed detail.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The six-rung dose ladder is not arbitrary. Mounjaro works as a dual GIP and GLP-1 receptor agonist, activating two gut-hormone pathways simultaneously, a mechanism that produces meaningful appetite suppression but also, especially early on, gastrointestinal side effects including nausea, bloating, loose stools and indigestion. Starting gently at 2.5 mg gives most people a chance to settle into treatment before the active range begins.
The jump from one dose to the next happens no sooner than four weeks in, and in practice many people stay at a given dose for longer if side effects are still noticeable or if life events (a holiday, an illness, surgery) make it sensible to hold steady. That pause is not a failure; it is the system working correctly. A prescriber reviewing your progress will weigh current tolerability, recent weight trajectory, and any other relevant health factors before deciding whether to move up. No dose change should happen on a timer alone.
Practically: whichever dose you are on, the pen lives in the fridge between uses, keeping the medicine at 2–8 °C. Check the Patient Information Leaflet for the exact window you have once a pen is taken out, that detail matters more than most people realise, and varies by storage conditions.
A starting BMI, on its own, does not decide which dose you ultimately reach. Prescribers consider the full clinical picture: comorbidities, concurrent medicines, how your body has responded so far, and any conditions that might make a faster or slower titration sensible. For example, people managing type 2 diabetes alongside weight loss may have different considerations than those treating weight alone.
Understanding what Mounjaro is and how it works can help frame why this individual calibration matters. The trial evidence from SURMOUNT-1 (involving around 2,500 adults over 72 weeks) found average weight reductions of roughly 20–21% at the 15 mg dose. But that figure comes from a population; for any individual, the dose that delivers the best balance of benefit and tolerability may be lower. The highest tolerated dose is the goal, not 15 mg as a default endpoint.
If you are curious about what the maximum dose looks like in practice, our page on the maximum dose of Mounjaro covers that in detail. And if you are wondering how the volume inside the pen relates to the milligram dose, that is answered separately on our Mounjaro dosage in ml page.
The most common side effects of Mounjaro are gastrointestinal, nausea at the top, followed by constipation, diarrhoea, indigestion and fatigue. They tend to peak in the days after a new dose or dose increase, then ease. The NHS describes this pattern and gives practical guidance on managing it, which is worth reading alongside your Patient Information Leaflet.
What this means for the dosage decision is real: if side effects at your current level are genuinely disruptive, your prescriber may recommend staying put rather than stepping up. There is nothing in the licensed schedule that requires you to reach 15 mg, and for some people a lower maintenance dose is both well-tolerated and clinically effective.
On the other hand, if NICE's recommendation threshold matters to your situation (NICE recommends reviewing continuation if there is less than 5% weight loss after six months at the highest tolerated dose) your prescriber will factor that into your dose review too. A detailed look at how doses appear across the full pen range is on our Mounjaro pens and dosage page. For a visual summary of the titration sequence, the Mounjaro dosage chart lays it out clearly.
Because dosage decisions are genuinely individual, the starting point is always a proper clinical assessment, not a default protocol. At nume, every consultation is read the same day by a GPhC-registered Independent Prescriber, a real clinician who reviews your full health picture before any prescription is issued.
There is a cost to treatment, and it is worth understanding what is (and is not) included in any price you see quoted. Our weight-loss treatments page sets out what is covered at nume clearly, so you can compare like for like. For context on what drives private treatment pricing in the UK more broadly, our weight loss overview covers the landscape honestly.
If you are already on Mounjaro and want to understand what your current dose looks like expressed differently, the dosage in units page explains that conversion. Questions about a specific dose (the 5 mg step in particular) are answered on our Mounjaro 5 mg page. Ready to have a prescriber look at your individual situation? Check your eligibility through a free consultation at nume and get a clinical answer, not a general one.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.